Goldman Sachs Upgrades Beta Bionics (BBNX) to Buy, Raises PT to $26 on Strong Growth and Market Outlook [Yahoo! Finance]
Beta Bionics, Inc. (BBNX)
Company Research
Source: Yahoo! Finance
Buy from Neutral with a price target of $26, which was upgraded from $18. Goldman Sachs' analysis of the diabetes technology market shows sustained growth and profitability for Beta Bionics. Earlier in the second quarter of 2025, Beta Bionics saw a significant 54% year-over-year increase in net sales, reaching $23.2 million. This growth was mirrored in patient adoption, with a 57% increase in new patient starts, totaling 4,934 new patients adopting the islet system. Concurrently, the gross margin showed an improvement to 53.8%. Goldman Sachs Upgrades Beta Bionics (BBNX) to Buy, Raises PT to $26 on Strong Growth and Market Outlook 15 States with the Best Healthcare in the US To boost market reach, the company expanded its sales force by 20 territories. Reflecting this performance and optimism, Beta Bionics raised its full-year 2025 net sales guidance to between $88 million and $93 million, up from the previous forecast of $82 million to $87 million. Beta Bionics Inc. (NASDAQ:
Show less
Read more
Impact Snapshot
Event Time:
BBNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BBNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BBNX alerts
High impacting Beta Bionics, Inc. news events
Weekly update
A roundup of the hottest topics
BBNX
News
- Beta Bionics (NASDAQ:BBNX) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Beta Bionics Announces Participation at Upcoming Investor ConferencesGlobeNewswire
- Beta Bionics (NASDAQ:BBNX) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=BBNX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</MarketBeat
- Beta Bionics, Inc. (NASDAQ:BBNX) Released Earnings Last Week And Analysts Lifted Their Price Target To US$28.10 [Yahoo! Finance]Yahoo! Finance
- Beta Bionics (NASDAQ:BBNX) was given a new $32.00 price target on by analysts at Truist Financial Corporation.MarketBeat
BBNX
Earnings
- 10/28/25 - Beat
BBNX
Sec Filings
- 12/4/25 - Form 144
- 12/4/25 - Form 4
- 12/4/25 - Form 4
- BBNX's page on the SEC website